STOCKHOLM – Medivir AB (NASDAQ Stockholm: MVIR), a biopharmaceutical company specializing in cancer drug development, announced today an increase in its number of shares and votes following recent share issues. The company completed a rights issue on November 7, 2023, and a directed share issue to Hallberg Management AB on January 22, 2024. These transactions resulted in a total increase of 56,211,817 ordinary shares.
As of the last trading day of January, Medivir has a total of 112,917,968 shares, comprising 112,053,218 ordinary shares and 864,750 class C-shares. The total number of votes amounts to 112,139,693, with each ordinary share entitled to one vote and each class C-share entitled to one-tenth of a vote.
Medivir’s operations are centered on the development of innovative drugs for cancer treatment, specifically in areas with high unmet medical needs. The company’s current focus is on fostroxacitabine bralpamide (fostrox), a pro-drug aimed at treating liver cancer with minimal side effects. Collaborations and partnerships are a significant aspect of Medivir’s business strategy, with drug development being pursued independently or in conjunction with partners.
The company’s share is listed on the Nasdaq Stockholm Small Cap list. This information, required to be disclosed under the Swedish Financial Instruments Trading Act, was released for publication at the time stated by the company’s news distributor.
The announcement of the share and vote increase is based on a press release statement from Medivir.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.